The FDA has approved delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.
Delafloxacin is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and is available in both IV and oral formulations.
Delafloxacin is indicated in adults for the treatment of ABSSSI caused by
JUNE 26, 2017